Superworth

Travere Therapeutics EPS TVTX

Diluted earnings per share by quarter and over the last twelve months, from 2011.

Last 12 months, to Jun 30, 2026
−$0.46
Latest quarter, Q2 FY26
−$0.37
Fiscal year 2025
−$0.30

Travere Therapeutics' earnings per share was −$0.46 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.37.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.30n/a
FY2024−$4.10n/a
FY2023−$1.61n/a
FY2022−$4.37n/a
FY2021−$3.03n/a
FY2020−$3.37n/a
FY2019−$3.46n/a
FY2018−$2.54n/a
FY2017−$1.56n/a
FY2016−$1.84−183%
FY2015$2.23n/a
FY2014−$6.04n/a
FY2012n/an/a
FY2012n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.37n/a−$0.46
Q1 FY26−$0.40n/a−$0.23
Q4 FY25$0.03n/a−$0.30
Q3 FY25$0.28n/a−$1.06
Q2 FY25−$0.14n/a−$2.04
Q1 FY25−$0.47n/a−$2.81
Q4 FY24−$0.73n/a−$4.10
Q3 FY24−$0.70−136%−$4.55
Q2 FY24−$0.91n/a−$1.88
Q1 FY24−$1.76n/a−$2.10
Q4 FY23−$1.18n/a−$1.61
Q3 FY23$1.97n/a−$1.46

Against its peers

Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
TVTXTravere Therapeutics−$0.46
INDVIndivior Pharmaceuticals$2.78+227% a year
ARQTArcutis Biotherapeutics$0.22
LQDALiquidia$1.39
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
LGNDLigand Pharmaceuticals$9.40
OGNOrganon$0.77−71% a year
AMRXAmneal Pharmaceuticals$0.49+4800% a year
ALKSAlkermes plc.$0.38−82% a year
NRIXNurix Therapeutics$2.31
TGTXTG Therapeutics$2.74+641% a year
Peer median$1.18

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Travere Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.